Vivani Medical, Inc. (VANI)
NASDAQ: VANI · Real-Time Price · USD
1.020
-0.030 (-2.86%)
Apr 1, 2025, 3:42 PM EDT - Market open
Vivani Medical Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
44
Market Cap
60.42M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
VANI News
- 1 day ago - Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 5 days ago - Vivani Medical Announces $8.25M Private Placement Equity Financing - GlobeNewsWire
- 6 days ago - Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing - GlobeNewsWire
- 8 days ago - Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025 - Business Wire
- 19 days ago - Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults - Business Wire
- 20 days ago - Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business - Business Wire
- 20 days ago - EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value - Benzinga
- 3 months ago - Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia - Business Wire